Yongxin Zhao, Ph.D. from University of Illinois at Chicago, Postdoctoral fellow at Cornell University Graduate School of Medicine and Memorial Sloan-Kettering Cancer Center, He has been engaged in cancer research for more than 20 years. Dr. Zhao has been a well-known scientist in the ADC field. He has 67 invention patents (42 were authorized) and published 27 professional articles. In his early years, he was engaged in drug process research and development in Monsanto (later Pharmacia) in the United States, and then conducted ADC research in ImmunoGen, Inc. in the United States for 12 years. As a technical leader, he has successively participated in the technology transfer and cooperation projects with 12 pharmaceutical companies related to ADC drugs, as well as the designing, process optimization, clinical study and marketing processes of T-DM1. Dr. Robert Yongxin Zhao is also a special reviewer of J. Med. Chem., Bioconj. Chem. and ACS Med. Chem. Lett journals in the United States, and a member of the National "Thousand Talents Program" Biomedicine Professional Committee.